Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

"I would come out of the shower and still have flakes on my scalp, and was confused because I had just washed my hair." The actress shared that she mainly sees her plaque psoriasis behind her ears ...

It most commonly develops on the: knees elbows scalp trunk Psoriasis can affect ... psoriasis on your feet and how it can be treated. Plaque psoriasis is the most common type of psoriasis.

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear skin, according to an interim analysis of a phase 3 trial.

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Investigators compared outcomes among patients with psoriasis undergoing apremilast treatment with genital involvement versus those without genital involvement.

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Pilar cysts can last for years or may go away on their own. Scalp psoriasis is a chronic skin condition characterized by thin, silvery scales in patches on your scalp. Sometimes these scales can ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

Rates of scalp clearance at 16 weeks were 72% with ... or the treatment of moderate-to-severe plaque psoriasis: results through week 24 of the phase III, randomized, double-blinded, placebo ...

Moderate to severe scalp psoriasis severely affects quality ... for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. The study included ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from ...